Quantitative assessment of lung cancer associated with genes methylation in the peripheral blood. (1st May 2013)

• Record Type: Journal Article
• Authors: Tan, Shanjuan; Sun, Changqing; Wei, Xiaoling; Li, Yanqiang; Wu, Yongjun; Yan, Zhen; Feng, Feifei; Wang, Jing; Wu, Yiming
• Is Part Of: Experimental lung research. Volume 39:Number 4/5(2013:Apr.)
• Page Start: 182
• Page End: 190
• Publication Date: 2013-05-01
• Subjects: Lungs -- Periodicals; Lungs -- Diseases -- Periodicals; Lung Diseases; Lung -- physiology; Respiratory System; 616.24
• DOI: 10.3109/01902148.2013.790096
• Languages: English
• ISSNs: 0190-2148

Abstract

<abstract> <title>ABSTRACT</title> <p> <italic>Background</italic>: Lung cancer is the leading cause of cancer-related deaths worldwide due mainly to late diagnosis and poor prognosis. Aberrant promoter methylation is an important mechanism for silencing of tumor suppressor genes during carcinogenesis and a promising tool for the development of molecular biomarkers. <italic>Methods</italic>: We evaluated the p16, RASSF1A, and FHIT genes promoter methylation status in peripheral blood DNA between 200 lung cancer patients and 200 normal controls by using SYBR green-based quantitative methylation-specific PCR (qMSP). <italic>Results</italic>: There were statistically significant differences in the methylation status of p16, RASSF1A, and FHIT between the cancer cases and controls (p16: <italic>P</italic> = .008, RASSF1A: <italic>P</italic> = .038, FHIT: <italic>P</italic> = .002). When the subjects were categorized into quartiles based on the genes methylation status, the risk of lung cancer was found to increase as methylation status increased (p16: <italic>P<sub>trend</sub></italic> = .002, RASSF1A: <italic>P<sub>trend</sub></italic> = .014, FHIT: <italic>P<sub>trend</sub></italic> = .001). When the median of methylation status was used as the cutoff between high and low methylation status, individuals with high methylation status were at a significantly higher risk of lung cancer than those with low methylation status (p16: adjusted odds ratio = 1.597, <italic>P</italic> = .028; RASSF1A: adjusted odds ratio = 1.551, <italic>P</italic> = .039; FHIT: adjusted odds ratio = 1.763, <italic>P</italic> = .008). In addition, there were no significant correlations between p16, RASSF1A, or FHIT methylation status and gender (<italic>P</italic> > .05), age (<italic>P</italic> > .05), smoking history (<italic>P</italic> > .05), histological type (<italic>P</italic> > .05), or clinical stage (<italic>P</italic> > .05). <italic>Conclusions</italic>: These results suggest that the high methylation statuses of p16, RASSF1A, or FHIT genes were associated with a significantly increased risk of lung cancer; the risk of lung cancer increased as the methylation status increased. Further investigation of their definitive usefulness in clinical practice is warranted.</p> </abstract>